Beijing Gene Key registers Phase 1 test of allogeneic cell therapy GKL-006Allo
The China-based trial will test safety and dose-limiting toxicity of an allogeneic cell injection in pretreated tumors, with no disclosed molecular target yet to benchmark it against rivals.
Executive Summary
- Beijing Gene Key Life Technology has registered a first-in-human study of an allogeneic cell therapy in patients whose tumors have already failed standard treatment, setting up a multi-year test of tolerability before any efficacy read is possible.
- The design prioritizes safety and dose-limiting toxicity over tumor response, reflecting an early dose-finding stage rather than a bid for near-term proof of clinical benefit.
- The sponsor's clinical portfolio now consists of two allogeneic cell therapy programs in the same tumor setting, both still in early planning stages rather than active recruitment.
- The trial enters a tumor field dominated by small-molecule and antibody mechanisms already in later-stage testing, leaving cell therapy a sparsely represented approach in this specific competitive set.
The registration
The trial, filed under NCT07704515, will test GKL-006Allo Injection, a non-CAR cell therapy, in patients 18 to 75 years old with unresectable locally advanced or metastatic tumors that have failed standard treatment. The study is Not yet recruiting, with a planned start date of August 30, 2026, and a China-only site footprint. Enrollment is anticipated at 27 patients in a second-line-or-later population. NCT07704515GKL-006Allo Injection in Patients With Advanced Solid TumorsNCT07704515
What the trial measures
The registered primary endpoints are the incidence and severity of adverse events and the number of participants with dose-limiting toxicities, assessed through 28 days after dosing with safety monitoring extending to 18 months. Secondary measures include objective response rate, disease control rate, progression-free and overall survival by RECIST v1.1, pharmacokinetic characterization, and immunogenicity testing for anti-drug and anti-HLA antibodies. That structure is a dose-escalation and tolerability study: the trial is built to characterize a safe regimen and immunogenicity profile for an allogeneic (donor-derived) cell product, not to establish efficacy in this population. NCT07704515GKL-006Allo Injection in Patients With Advanced Solid TumorsNCT07704515
Timeline
The primary completion date is set for September 30, 2028, with overall study completion targeted for January 31, 2029, a total planned trial duration of 932 days from first dose to primary completion. That places any dose-limiting toxicity or safety readout more than two years out from the trial's planned August 2026 start, consistent with a first-in-human program still in its dose-escalation planning phase. NCT07704515GKL-006Allo Injection in Patients With Advanced Solid TumorsNCT07704515
Sponsor pipeline
Beijing Gene Key Life Technology's clinical portfolio consists of two trials, both currently Not yet recruiting, with GKL-006Allo Injection as one of two allogeneic cell therapy candidates in advanced tumors. A related program from an affiliated developer, Beijing Geekgene Technology Co., LTD's GK01 Cell Injection, is already recruiting in the same tumor setting with a primary completion date of February 12, 2027.
Competitive landscape
Advanced tumors carry an active field of at least 8 comparable trials, but the named entrants use small-molecule, antibody, or RNA mechanisms rather than cell therapy: Merck's belzutifan targets HIF-2α, OncoC4's gotistobart targets CLPP, and ModernaTX's mRNA-4359 targets PD-1, none of which share GKL-006Allo's cell-therapy modality or mechanism class. Cell Therapy (Non-CAR) accounts for 9 of the trials run in this indication historically, a small share of overall activity, making this modality a minority approach in a field otherwise dominated by small-molecule and biologic mechanisms. The trial's molecular target is not characterized in its registry entry, so competitive positioning here rests on modality and indication rather than a specific mechanism comparison.
What would matter next
Given a tumor field where cell therapy remains a minority modality and no validated cell-therapy mechanism has been established against this population's standard of care, a signal that GKL-006Allo clears its dose-limiting toxicity bar with a manageable adverse-event profile, and shows any disease control by RECIST v1.1 in the dose-expansion cohort, would be the first evidence that the approach warrants a larger trial.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.